"hPL has favorable properties in terms of ethics and scientific practice and should seriously be considered as a new standard cell culture medium substitute". This is only one of the results highlighted in the current academic article 'Human Platelet Lysate can Replace Fetal Calf Serum as
Despite the challenging times, we would like to wish you and your families a happy Easter. We hope that you and your loved ones are healthy and safe. We certainly continue to support your business with our cell culture supplements. We adapted our processes to provide
The article by Domenik Egger et al. demonstrates the advantages of PL Matrix over other compareable products. The article was published in the Stem Cell Research & Therapy journal and is titled „ From 3D to 3D: isolation of mesenchymal stem/stromal cells into three-dimensional human
From 4th to 5th December, PL BioScience attended the Cell Therapy Manufacturing & Gene Therapy Congress 2019 in Amsterdam. The scope of the congress were advances in cell and gene therapy, especially innovations in new therapy methods. Furthermore, challenges and barriers were presented and discussed in
On November 18th, our CEO, Hatim Hemeda and our CFO, Christian Wilkes, represented PL BioScience at the DxPx conference in Düsseldorf. Although the scope of the conference were mainly diagnostics and digital health, Hatim and Christian were able to socialise and met new potential partners.
From 4th to 5th December, PL BioScience will attend the Cell Therapy Manufacturing & Gene Therapy Congress 2019 in Amsterdam. The scope of the congress is to present and share the latest advances and innovations in cell and gene therapy. Furthermore, challenges and barriers will
On 15th October, our CFO Christian Wilkes represented PL BioScience in the final round of theBioRiverBoost! 2019 contest. Being among eight other finalists, Christian held a pitch about our xeno-free growth promoting products and our company. At the core of the BioRiver Boost! 2019 were ground-breaking innovations and
From 23-25 September, PL BioScience attended the 7th German Stem Cell Network (GSCN) Conference in Berlin. The scope of the conference was to foster basic and applied stem cell research. We had many interesting and positive talks and could socialise with new potential partners and
The essay by Toni Lindl and Gerhard Gstraunthaler demonstrates the fatal disadvantages of Fetal Bovine Serum (FBS). The article published in the German scientific magazine 'Laborjournal' proposes a contemporary cell culture solution: Human Platelet Lysate (hPL). The authors highlight the reproducibility of trial results achieved with
The PL BioScience team participated in the AC² Innovation Award ceremony in the historic city hall of Aachen. During the event, the winner of the award has been announced. PL BioScience was nominated as one of 5 'technologies of the future'. Although the whole team kept their
PL BioScience is mentioned in the local newspaper ‘Aachener Zeitung’ one more time. Prior to the award ceremony on 6 June 2019, PL BioScience is presented in the recent press article as one of the five finalists. Our whole team is delighted about the appreciation and innovative strength
PL BioScience ensures its Good Manufacturing Practice throughout all process steps. We strive to offer high-quality services - from manufacture to the advise of our customers. For that reason, we established a holistic quality management system underlining our own commitment to quality. Recently, our Good Manufacturing
PL BioScience in 'Journal of the Chamber of Industry and Commerce Aachen' (Wirtschaftliche Nachrichten der Industrie- und Handelskammer Aachen) As one of the five finalists of the AC² Innovation Award 2019, we were able to present our patent-protected technologies to the Journal. The recent report pictures our novel cell
PL BioScience's technology in the local newspaper 'Aachener Zeitung'. Our platelet-based technology is one out of five 'technologies of the future' nominated for the AC² Innovation Award 2019 which honours one local laureate with unique innovative strength. 'Aachener Zeitung' has just presented the five finalists which have the opportunity
With our novel 2D and 3D cell culture media, we made it to the final round of the AC² Innovation Award 2019 for the Aachen region. Our technology based on human blood platelets is one out of five 'technologies of the future' nominated for the award.
The five finalists of the AC² Innovation Award 2019 for the Aachen region have just presented their technologies to the jury. Beforehand, the AGIT (Aachen Society for Innovation and Technology Transfer), the chambers and universities selected numerous local companies with innovative strength. We are very pleased to
"We demonstrate that human platelet lysate (hPL) can replace hS in macrophage cultivation [
The state-of-the-art workshop on the use of human Platelet Lysate for cell therapy was sponsored by PL BioScience. The meeting took place 22‐23 March 2018 in Zurich (Switzerland). Currently, the summarising Committee Report was published. The main stakeholders in the hPL area focused on the question: 'How can hPL further
We wish you a joyful Holiday Season and a happy and successful New Year! We are grateful for the confidence of our customers and partners and look forward to joint projects in 2019.
As one of RWTH Aachen University's Spin-offs, we participated in todays meeting of the science council We are proud to present PL BioScience and our innovative Platelet Lysate-based technologies to the science council. Next to the contact with the members of the council, we enjoyed the exchange
